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Abstract  27 
RNA modulating factors not only regulate multiple steps of cellular RNA metabolism, but 28 
also emerge as key effectors of the immune response against invading viral pathogens 29 
including human immunodeficiency virus type-1 (HIV-1). However, cellular RNA 30 
binding proteins involved in the establishment and maintenance of latent HIV-1 31 
reservoirs have not been extensively studied. Here, we screened a panel of 62 cellular 32 
RNA binding proteins and identified NEDD4 binding protein 1 (N4BP1) as potent 33 
interferon-inducible inhibitor of HIV-1 in primary T cells and macrophages. N4BP1 34 
harbors a prototypical PIN-like RNase domain and inhibits HIV-1 replication by 35 
interacting with and degrading viral mRNA species. Upon activation of CD4+ T cells, 36 
however, N4BP1 undergoes rapid cleavage at Arg509 by the paracaspase MALT1. 37 
Mutational analyses and knockout studies revealed that MALT1-mediated inactivation 38 
of N4BP1 facilitates the reactivation of latent HIV-1 proviruses. Taken together, our 39 
findings demonstrate that the RNase N4BP1 is an efficient restriction factor of HIV-1 and 40 
suggest that inactivation of N4BP1 by induction of MALT1 activation might facilitate 41 
elimination of latent HIV-1 reservoirs. 42 
43 





Host cells are equipped with sophisticated mechanisms to prevent or inhibit viral 45 
infection. HIV-1 replication, for example, is targeted by a plethora of restriction factors 46 
including APOBEC3, TRIM5α, Tetherin, SAMHD1, GBP5 and MX2 1-10. Although 47 
these factors may suppress HIV-1 replication at various steps through multiple 48 
independent mechanisms, they are usually counteracted or evaded by the virus. Another 49 
characteristic shared by many host restriction factors is their inducibility by type I 50 
interferons (IFNs), which play a pivotal role in the host defense against viral infection 51 
11,12. 52 
 In search of novel effective antiretroviral mechanisms, nucleic acid binding 53 
proteins are of particular interest since they are not only important regulators of antiviral 54 
gene expression, but may also act as direct effectors of the antiviral immune response  55 
13,14. Furthermore, they may modulate sensing of viral infection by binding to and/or 56 
degrading viral RNA or DNA species or by directly acting as pattern recognition 57 
receptors. One example of a nucleic acid-binding protein with antiviral activity is the 58 
zinc-finger antiviral protein (ZAP). Initially, ZAP was shown to degrade mouse leukemia 59 
virus (MLV) RNA by recruiting the exosome complex 15,16. ZAP recognizes RNA 60 
sequences enriched in CG dinucleotides, which are suppressed in the genomes of HIV-1 61 
and many other vertebrate viruses 17. As a result, HIV-1 engineered to contain a higher 62 
number of CG dinucleotides is more sensitive to ZAP than the respective parental virus. 63 
Another example of an antiviral nucleic acid binding protein is SAMHD1. This dNTP 64 
triphosphohydrolase blocks HIV-1 reverse transcription in myeloid cells and resting T 65 
cells by depleting cellular dNTP pools 9,10,18. Finally, the endoribonuclease Regnase-1 66 
(also known as MCPIP1) has been suggested to degrade retroviral mRNAs 19. Given the 67 
large number of human RNA binding proteins identified in recent studies 20,21, it seems 68 
highly likely that additional RNA binding proteins with key roles in antiviral immunity 69 
remain to be discovered. As the example of SAMHD1 illustrates 22,23, some of these 70 




restriction factors might be preferentially active in resting CD4+ T cells and play a role in 71 
the establishment and maintenance of latent HIV-1 reservoirs.  72 
 To discover novel restriction factors targeting viral RNA, we screened a 73 
collection of cellular proteins containing various RNA binding domains for 74 
antiretroviral activity.   75 





Identification of N4BP1 as a host factor inhibiting HIV-1 77 
To identify as-yet-unknown host restriction factors suppressing HIV-1 replication by 78 
binding to viral RNA, we selected 62 expression plasmids from mammalian gene 79 
collection (MGC) clones encoding proteins harboring at least one RNA binding domain, 80 
such as CCCH- or CCHC-type Zinc Fingers (ZF), KH domains or RNase folds (see 81 
Supplementary Table 1), since proteins harboring these domains may be involved in the 82 
suppression of HIV-1 17,19. We co-transfected HEK293T cells with the infectious HIV-1 83 
NL4-3 molecular clone and the 62 expression plasmids, and determined infectious HIV-1 84 
yield in the culture supernatants by infecting TZM-bl indicator cells 48 hours 85 
post-transfection. Of the 62 proteins analyzed, NEDD4 binding protein 1 (N4BP1) was 86 
the most potent inhibitor, decreasing infectious HIV-1 NL4-3 production by >20-fold 87 
(Fig. 1a). Immunoblot analysis of cells producing HIV-1 NL4-3 or the primary HIV-1 88 
isolate AD17 revealed that N4BP1 expression decreased the expression of viral Env and 89 
Gag proteins in a dose-dependent manner (Fig. 1b). Analyzing a broader panel of 90 
primate lentiviruses, including transmitted/founder (TF) and chronic control (CC) 91 
HIV-1 strains, we found that N4BP1 reduced infectious yield of all HIV-1, HIV-2 and 92 
SIVcpz strains examined (Fig. 1c and Supplementary Fig. 1). Thus, N4BP1 is a broad 93 
and potent inhibitor of evolutionarily diverse primate lentiviruses. 94 
 95 
N4BP1 is IFN-inducible and restricts HIV-1 infection in human T cells 96 
Since antiretroviral host restriction factors are frequently inducible by IFN and virus 97 
infection, we examined if the expression of N4BP1 is IFN-inducible in T cells. IFN-α 98 
stimulation of Jurkat T cells increased N4BP1 expression at both the mRNA and protein 99 
level (Fig. 2a and 2b). Similarly, N4BP1 expression was induced about 3-fold by IFN-α 100 
stimulation in CD4+ T cells from healthy human donors (Fig. 2c). Notably, all 12 human 101 
IFN-α subtypes, but not IL-27, increased N4BP1 protein levels by about 2- to 4-fold in 102 




primary CD4+ T cells (Supplementary Fig. 2a and 2b). Furthermore, HIV-1 NL4-3 103 
infection induced the expression of mRNAs encoding IFN-β, N4BP1 and the 104 
IFN-inducible proteins Tetherin/BST-2 and ISG15 in Jurkat cells (Fig. 2d). N4BP1 gene 105 
expression was also significantly upregulated in the spleens of HIV-1 infected humanized 106 
mice (Fig. 2e). Collectively, these data show that N4BP1 is a type I IFN- and 107 
HIV-1-inducible protein with potent anti-HIV-1 activity.  108 
To determine whether endogenous N4BP1 restricts HIV-1 in human T cells, we 109 
used the CRISPR/Cas9 system to generate seven Jurkat cell lines lacking N4BP1 110 
expression (Fig. 2f, left panel). HIV-1 replicated with faster kinetics in all seven 111 
N4BP1-deficient (KO) cell lines compared to Cas9-expressing control cells in response to 112 
HIV-1 infection (MOI 0.01) (Fig. 2f, right panel). Reconstitution of N4BP1 expression 113 
via a doxycycline-inducible Tet-on system (Fig. 2g, left panel) rescued inhibition of 114 
HIV-1 replication (Fig. 2g, right panel). Noteworthy, growth, apoptosis rates, or global 115 
protein synthesis were not altered between control and N4BP1 KO Jurkat cells without 116 
HIV-1 infection (Supplementary Fig. 3a-3c). Furthermore, N4BP1 deficiency did not 117 
affect the expression of a set of host genes such as IFNB and NFKBIA (Supplementary 118 
Fig. 4a). Consistently, the expression of IκBα, Tubulin-α and GAPDH proteins was not 119 
different between control and N4BP1 KO Jurkat cells (Supplementary Fig. 4b), 120 
suggesting that the anti-HIV-1 effect of N4BP1 is direct and not mediated by the 121 
regulation of host genes. In agreement with the results of N4BP1 KO cells, 122 
siRNA-mediated knockdown of N4BP1 in Jurkat cells (Supplementary Fig. 5a) resulted 123 
in a marked increase in viral RNA expression 72 h after infection with HIV-1 NL4-3, 124 
without significantly affecting IFNB expression levels (Supplementary Fig. 5b and 5c).  125 
Conversely, we also generated four Jurkat cell clones stably over-expressing 126 
N4BP1 or a control vector (Fig. 2h, left panel). N4BP1 over-expression fully prevented 127 
HIV-1 replication at low MOI (0.001) (Fig. 2h, central panel). Even at higher MOI 128 
(0.01), N4BP1 over-expression prevented or substantially delayed HIV-1 replication (Fig. 129 




2h, right panel). Furthermore, the expression of viral RNAs including tet/rev, vif and gag 130 
was suppressed in N4BP1 over-expressing Jurkat cells (Supplementary Fig. 5d and 5e). 131 
These results demonstrate that N4BP1 restricts HIV-1 replication in human T cells.  132 
Since two out of four N4BP1 overexpressing Jurkat cell clones allowed delayed 133 
but detectable replication of HIV-1 (Fig. 2h), we examined whether N4BP1 expression 134 
was altered in these cells following HIV-1 infection. To avoid artifacts due to differences 135 
in viral replication and spread of infection, we used an env-deficient (Δenv) 136 
VSV-G-pseudotyped HIV-1 NL4-3 construct (Supplementary Fig. 5f). Consistent with 137 
the results obtained with replication-competent HIV-1, production of Gag was suppressed 138 
in N4BP1 overexpressing cells compared to control cells in single cycle infection. 139 
Notably, however, N4BP1-mediated inhibition of Gag expression was less pronounced at 140 
higher MOI, suggesting that high amounts of HIV-1 may saturate the inhibitory effect of 141 
N4BP1. Furthermore, HIV-1 infection did not reduce N4BP1 expression levels 142 
(Supplementary Fig. 5f).  143 
 144 
N4BP1 restricts HIV-1 in primary macrophages 145 
IFN-α induced N4BP1 mRNA and protein expression not only in T cells (Fig. 2a-2c) but 146 
also in THP-1-derived macrophage-like cells (Fig. 3a and 3b). In addition, we found that 147 
N4BP1 is constitutively expressed in primary human monocyte-derived macrophages 148 
(MDMs) and further upregulated by IFN-α stimulation (Fig. 3c-3e). To examine the 149 
antiretroviral activity of N4BP1 in primary macrophages, we knocked down N4BP1 150 
using three different siRNAs (Fig. 3f) before infecting the cells with the 151 
macrophage-tropic HIV-1 strain AD8. The three N4BP1-specific siRNAs increased 152 
infectious HIV-1 AD8 yield by 6.5-, 10.8- and 2.6-fold, respectively, at day 3 and by 153 
16.2-, 14.8- and 4.3-fold by day 6 post-infection (Fig. 3g). Thus, N4BP1 restricts HIV-1 154 
in both CD4+ T cells and macrophages.  155 
 156 




N4BP1 degrades HIV-1 RNA 157 
To decipher the molecular mechanisms underlying the antiviral effect of N4BP1, we 158 
investigated whether its inhibitory activity is limited to HIV-1 and related primate 159 
lentiviruses. Overexpression of N4BP1 in HEK293T cells also inhibited MLV; genus 160 
Gammaretrovirus) and human foamy virus (HFV; genus Spumavirus) (Fig. 4a). However, 161 
N4BP1 failed to suppress influenza A virus mRNA expression in HEK293T cells 162 
(Supplementary Fig. 6a). Furthermore, N4BP1 overexpression did not reduce 163 
production of infectious influenza A virus in HEK293T cells (Supplementary Fig. 6b), 164 
arguing against a general and unspecific effect of N4BP1 on viral RNA expression.  165 
Since N4BP1 reduces both HIV-1 mRNA and protein expression levels, we 166 
analyzed whether it affects proviral transcription via the long terminal repeat (LTR) using 167 
a reporter system expressing luciferase under the control of the viral LTR promoter. 168 
While NL4-3 Δenv induced reporter gene expression, co-expression of N4BP1 failed to 169 
suppress HIV-1 LTR-mediated gene expression (Supplementary Fig. 7a). In contrast, 170 
N4BP1 suppressed HIV-1 expressed under the control of the CMV promoter (pCMV259), 171 
but did not affect EGFP expression from the same promoter (Supplementary Fig. 7b 172 
and 7c). Together, these results suggest that N4BP1 suppresses HIV-1, but not EGFP, at a 173 
post-transcriptional level.  174 
N4BP1 was originally identified as a target of the E3 ubiquitin ligase NEDD4, 175 
resulting in its proteasomal degradation in the nucleolus and promyelocytic leukemia 176 
(PML) bodies 24,25. N4BP1 harbors a potential nuclease domain in addition to two KH 177 
domains, which represent canonical single-stranded nucleic acid binding domains (Fig. 178 
4b) 26. The nuclease domain of N4BP1 is highly conserved among mammalian species 179 
and structurally predicted to form a catalytic pocket with conserved aspartic acids (Fig. 180 
4c). Using a subgenomic sequence of HIV-1 NL4-3 as substrate, we found that 181 
recombinant N4BP1 degrades viral RNA in vitro (Fig. 4d and Supplementary Fig. 8a). 182 
Structural modeling of the human N4BP1 RNase domain revealed that it harbors a 183 




catalytic center whose structure and primary amino acid sequence is similar to that of 184 
Regnase-1 (Fig. 4e and Supplementary Fig. 8b). A point mutation of Asp623, which is 185 
predicted to be essential part of the catalytic center, to Asn (D623N) fully abrogated the 186 
RNase activity of N4BP1 (Fig. 4d). Importantly, structural modeling suggests that the 187 
D623N mutation does not alter the overall structure of the RNase domain of N4BP1 (Fig. 188 
4e).  189 
Consistently, Northern blot analysis showed that N4BP1 reduces un-, singly- 190 
and multi-spliced viral mRNAs in an RNase activity-dependent manner, while ribosomal 191 
RNA was not affected (Fig. 4f). In contrast, incoming viral RNA was not degraded as 192 
knockdown of N4BP1 did not significantly alter the amount of early or late reverse 193 
transcriptase (RT) products or the amount of integrated proviral DNA in infected Jurkat 194 
cells (Supplementary Fig. 8c).  195 
To test whether N4BP1 directly binds HIV-1 RNA, we performed an RNA 196 
immunoprecipitation (RIP) assay using the N4BP1 D623N mutant, in which the 197 
RNA-protein interaction is expected to be stable due to the lack of RNase activity. The 198 
RIP-qPCR assays revealed that the N4BP1 D623N mutant binds several HIV-1 mRNA 199 
species including splice products expressing Tat/Rev, Vif and Gag (Fig. 4g). In agreement 200 
with RNase-dependent restriction, wild-type N4BP1, but not the catalytically inactive 201 
mutant D623N suppressed viral protein expression (Fig. 4h and Supplementary Fig. 202 
8d) and infectious HIV-1 yield (Fig. 4i) without affecting cell viability (Supplementary 203 
Fig. 8e and 8f). Collectively, these data demonstrate that N4BP1 restricts HIV-1 204 
replication by binding and degrading viral mRNA species.  205 
 206 
MALT1 degrades N4BP1 in T cells upon TCR-mediated activation. 207 
Antiretroviral restriction factors are often counteracted by HIV-1 accessory proteins. 208 
N4BP1, however, inhibited wild-type HIV-1 NL4-3 and a mutant lacking all four 209 
accessory proteins (NL4-3 Δ4) with similar efficiencies (Supplementary Fig. 9). Thus, 210 




we next examined N4BP1 expression levels in activated CD4+ T cells that are highly 211 
permissive for HIV-1 replication and resting T cells thought to represent the main 212 
reservoir of latent HIV-1. Interestingly, N4BP1 protein levels were drastically decreased 213 
in primary CD4+ T cells activated with phorbol 12-myristate 13-acetate (PMA) plus 214 
ionomycin or by treatment with anti-CD3/CD28 antibodies, but not with IFN-γ or IL-2 215 
(Fig. 5a). Kinetic analysis revealed that N4BP1 levels started to decrease at 0.5 h after 216 
PMA/ionomycin stimulation and remained undetectable for at least 8 hours (Fig. 5b). 217 
Notably, N4BP1 mRNA levels were not markedly affected by PMA/ionomycin 218 
treatment (Supplementary Fig. 10a). In support of N4BP1 protein degradation, a ~72 219 
kDa cleavage product appeared in PMA/ionomycin-treated cells (Fig. 5b) just above 220 
non-specific bands (65 kD and 40 kD) which is also present in N4BP1 KO cells (Fig. 221 
2f). Although N4BP1 was reported to undergo NEDD4-mediated polyubiquitination 25, 222 
proteasome inhibitor treatment did not prevent PMA/ionomycin-mediated degradation 223 
of N4BP1 (Supplementary Fig. 10b). Further experiments revealed that PMA alone, 224 
but not ionomycin, is sufficient to decrease N4BP1 levels (Supplementary Fig. 10c). 225 
Similar to T cell receptor (TCR) signals, PMA activates signaling pathways via the 226 
CARMA1-BCL10-MALT1 signalosome 27. MALT1 is known to cleave RNA binding 227 
proteins Regnase-1 and Roquin proteins28,29. Consistent with a previous report, 228 
overexpression of Regnase-1 also suppressed infectious HIV-1 NL4-3 production, 229 
whereas expression Roquin-1 or -2 had no inhibitory effect (Supplementary Fig. 10d). 230 
We therefore hypothesized that N4BP1 might also be cleaved by MALT1. Indeed, 231 
knockout of MALT1 in Jurkat cells abrogated degradation of N4BP1 in response to 232 
stimulation (Fig. 5c). Furthermore, the MALT1 inhibitor zVRPR-fmk, but not a 233 
pan-caspase inhibitor zVAD-fmk, suppressed cleavage of N4BP1 (Fig. 5d). Thus, the 234 
protease activity of MALT1 is essential for N4BP1 cleavage upon T cell activation.  235 
 236 
MALT1 cleaves N4BP1 at R509 237 




The appearance of a ~72 kDa cleavage product (Fig. 5b) suggested that the MALT1 238 
cleavage site(s) is located in the central region of N4BP1, between the KH and RNase 239 
domains (Fig. 5e). Thus, we generated a series of C-terminally truncated variants to 240 
determine the exact position of the cleavage site (Fig. 5e). Immunoblot analysis 241 
revealed that the electrophoretic mobility of an N4BP1 mutant comprising the 242 
N-terminal 500 amino acids was close to that of MALT1 cleaved N4BP1 (Fig. 5f). 243 
MALT1 specifically cleaves after arginine residues 27, and analysis of previously 244 
identified MALT1 substrates revealed a putative [S/P]-R-G consensus target sequence 245 
for this protease (Fig. 5g and Supplementary Fig. 10e). N4BP1 harbors a highly 246 
conserved SRG motif at positions 508-510 (Fig. 5h), and R509A mutant N4BP1 was 247 
not cleaved by MALT1 expressed together with BCL10 (Fig. 5i). Furthermore, 248 
PMA/ionomycin stimulation of Jurkat cells induced cleavage of WT Flag-N4BP1, while 249 
the Flag-N4BP1 R509A mutant was resistant to cleavage (Fig. 5j). Notably, mutation of 250 
R509A rendered N4BP1 resistant to MALT1 cleavage without impairing its antiviral 251 
activity (Fig. 5k). 252 
 253 
Degradation of N4BP1 promotes reactivation of latent HIV-1  254 
Degradation of N4BP1 by MALT1 might be involved in the reactivation of latent HIV-1 255 
by T cell activation. To investigate this possibility, we first examined N4BP1 expression 256 
in three different human T cell lines harboring latent HIV-1 proviruses 30-32. N4BP1 was 257 
constitutively expressed and downmodulated upon PMA stimulation in all cell lines 258 
tested (Supplementary Fig. 11a-c). As expected, PMA-induced degradation of N4BP1 259 
was abrogated in MALT1 knockout JNLGFP, J-Lat10.6 and J-Lat5A8 cells (Fig. 6a, 6b, 260 
Supplementary Fig. 11d). Thus, MALT1 is required for PMA-induced degradation of 261 
N4BP1 in latently HIV-1 infected T cells. MALT1-knockout JNLGFP, J-Lat10.6 and 262 
J-Lat5A8 cells showed significantly lower levels of HIV-1 reactivation than control 263 
cells in response to PMA stimulation (Fig. 6c, 6d, and Supplementary Fig. 11e). After 264 




induced expression of N4BP1 in J-Lat10.6 and JNLGFP cells by a Tet-On system, 265 
wild-type but not R509A N4BP1 was degraded in response to PMA stimulation (Fig. 6e 266 
and 6f). Intriguingly, the MALT1-resistant N4BP1 R509A mutant suppressed the 267 
reactivation of J-Lat10.6 and JNLGFP cells more efficiently than WT N4BP1 as 268 
examined by the changes in HIV-1 p24 levels in the culture supernatants (Fig. 6e and 269 
6f). We further established N4BP1 KO JNLGFP cells (Fig. 6g), and reconstituted them 270 
with WT N4BP1 or the R509A mutant thereof using the inducible Tet-On system (Fig. 271 
6h). Consistent with the overexpression data, JNLGFP cells reconstituted with R509A 272 
N4BP1 potently suppressed reactivation of HIV-1, whereas cells reconstituted with 273 
wild-type N4BP1 failed to do so. (Fig. 6h and 6i). Thus, inactivation of N4BP1 by 274 
MALT1 supports latency reversal upon activation of latently HIV-1 infected T cells 275 
(Supplementary Fig. S12). 276 
277 





Our study demonstrates that HIV-1 latency and reactivation are controlled by N4BP1 at 279 
the post-transcriptional level. Notably, two mechanisms may contribute to the 280 
maintenance of viral latency by N4BP1: First, N4BP1 generally degrades spliced- and 281 
un-spliced HIV-1 transcripts, thereby preventing their translation into viral proteins and 282 
progeny virion formation. Second, N4BP1 may continuously keep HIV-1 Tat levels 283 
below the threshold required for reactivation and efficient transcription of viral genes. 284 
Intriguingly, N4BP1 is rapidly inactivated by MALT1 in response to stimuli inducing 285 
HIV-1 reactivation, indicating that changes in MALT1 activation levels regulate HIV-1 286 
reactivation. Thus, manipulation of MALT1 activity may be a promising approach to 287 
control HIV-1 latency and reactivation. Notably, treatment with the MALT1 inhibitor 288 
MI-2 has previously been shown to induce death of latently HIV-1 infected cells, and 289 
death rates were further increased by PMA stimulation 33. However, specificity of 290 
MALT1 inhibition and the MALT1 targets involved in this process remained unclear. 291 
Thus, further studies are required to decipher the suitability of MALT1 as a target for 292 
therapeutic intervention. 293 
 An important open question is how N4BP1 specifically recognizes retroviral 294 
RNA, without degrading for example Influenza A virus or ribosomal RNAs. Given that 295 
multi-spliced HIV-1 RNA (encoding Tat and Rev) as well as singly or un-spliced viral 296 
mRNAs are degraded, N4BP1 might target motifs or structures in un-spliced viral mRNA, 297 
the tat/rev encoding region or end modifications found in all three mRNA classes. The 298 
frequency of CG dinucleotides is markedly suppressed in the genomes of HIV-1 as well 299 
as other vertebrate viruses, thereby attenuating ZAP-mediated restriction 17. Given that 300 
N4BP1 suppresses various lenti- and retro-viruses including HIV-1, sequence motif(s) 301 
other than CG dinucleotides could be recognized by N4BP1.  302 
N4BP1 is localized in the nucleus especially in the nucleolus and/or PML bodies 303 
25. Intriguingly, HIV-1 transcripts are specifically re-localized into nucleoli for viral gene 304 




expression 34. In addition, latent HIV-1 was reported to colocalize with PML bodies, with 305 
PML binding to the latent HIV-1 LTR promoter 35. Degradation of PML led to the 306 
activation of viral transcription together with the release of histone methyltransferase G9a 307 
35. Given that HIV-1 RNA is suppressed by N4BP1, it is tempting to speculate that N4BP1 308 
co-transcriptionally degrades viral mRNA in PML bodies, thereby contributing to the 309 
maintenance of latency. Although MALT1 is majorly present in the cytoplasm, this 310 
protein harbors a nuclear export signal (NES), and is reported to shuttle between nucleus 311 
and cytoplasm 36. Thus, MALT1 might cleave N4BP1 in the nucleus.  312 
 Our data suggest that N4BP1 is not directly counteracted by HIV-1 accessory 313 
proteins. However, it is possible that HIV-1 has evolved means to evade N4BP1. 314 
Furthermore, expression of N4BP1 was diminished in T cells stimulated with 315 
PMA/ionomycin or via TCR-CD3/CD28 ligation. Considering that HIV-1 replicates 316 
efficiently in activated but not in quiescent CD4+ T cells, it is tempting to speculate that 317 
reduction of N4BP1 facilitates HIV-1 replication in activated T cells. We discovered that 318 
cleavage and inactivation of N4BP1 in T cells is mediated by the protease MALT1 and 319 
identified R509 as its cleavage site. Previously described MALT1 substrates include 320 
host mRNA regulators such as Regnase-1 and Roquin. These proteins are critical for 321 
controlling immune reactions as they destabilize host mRNAs encoding 322 
proinflammatory cytokines and proteins involved in T cell activation 37,38. It is 323 
intriguing to explore the function of N4BP1 in the control of immune responses and 324 
future studies will uncover the functional roles of N4BP1 in regulating host mRNAs in 325 
vivo.  326 
A recent study determining type I interferomes of fibroblasts in multiple 327 
vertebrate species identified 62 evolutionarily conserved interferon-stimulated genes 328 
(ISGs) 12. Interestingly, N4BP1 was also among these core ISGs. Upon IFN-α 329 
stimulation, N4BP1 suppresses HIV-1 infection by inducing its expression and/or 330 
altering its RNase activity. Additionally, the MALT1-cleavage site as well as the RNase 331 




domain are conserved among the N4BP1 orthologs of different mammalian species, 332 
consistent with IFN-inducibility. These notions imply that the function of N4BP1 in 333 
antiviral immunity is conserved among different species. Given that human N4BP1 334 
suppresses a variety of retroviruses, but not influenza A virus, it is tempting to speculate 335 
that N4BP1 might have an ancestral function in specifically controlling retroviral 336 
infection. Furthermore, it will be interesting to explore whether N4BP1 is involved in 337 
the post-transcriptional silencing of endogenous retroviruses. 338 
In this study, we identified N4BP1 as a HIV-1 restriction factor by screening 339 
proteins that harbor potential RNA binding domains. As our screening approach did not 340 
include all RNA binding proteins, it is possible that additional anti-retroviral RNA 341 
binding factors remain to be discovered. Furthermore, an over-expression-based 342 
screening approach may fail to identify antiviral proteins that are endogenously 343 
expressed to high levels, if over-expression does not further increase their abundance. 344 
Therefore, further studies are required to elucidate the role of RNA binding proteins in 345 
restriction of HIV-1, e.g. by using more complete sets of RNA binding proteins and/or 346 
loss of function screening systems.  347 
In summary, we identified N4BP1 as an RNase that functions as an antiretroviral 348 
restriction factor by degrading various HIV-1 mRNA species. Although further studies 349 
are required to precisely define the molecular mechanisms underlying target RNA 350 
recognition by N4BP1, our findings clearly demonstrate that N4BP1 is a potent effector 351 
of type I IFN-mediated anti-HIV-1 activity.  352 
  353 





Cell culture, Proviral Constructs and Transfection. 355 
Jurkat cells and THP-1 cells were obtained from the ATCC and grown in RPMI-1640 356 
medium (Nacalai Tesque) supplemented with 10% fetal calf serum (FCS) and 50 μM 357 
β-mercaptoethanol (Nacali Tesque). HEK293T cells were obtained from ATCC and 358 
grown in DMEM supplemented with 10% fetal calf serum (FCS). TZM-bl cells and 359 
J-Lat10.6 cells were obtained from the NIH AIDS Research and Reference Reagent 360 
Program and maintained in DMEM medium (Nacalai tesque) supplemented with 10% 361 
fetal calf serum (FCS) or in RPMI-1640 medium (Nacalai Tesque) supplemented with 362 
10% fetal calf serum (FCS) and 50 μM β-mercaptoethanol (Nacali Tesque) respectively. 363 
J-Lat5A8 cells were kindly provided by Warner C. Greene from the Gladstone Institute of 364 
Virology and cultured in RPMI-1640 supplemented with 10% fetal calf serum. JNLGFP 365 
cells were kindly provided by David N. Levy from the New York University College of 366 
Dentistry and cultured in RPMI1640 supplemented with 10% of FCS. Cell lines were not 367 
validated further or tested for micoplasma in our laboratory. Plasmid transfection 368 
experiments for HEK293T cells were performed using Polyethylenimine Max Mw 40000 369 
(polysciences). Plasmid transfection experiments for Jurkat cells were performed using 370 
Neon Transfection System (Invitrogen) according to the manufacturer’s protocol. 371 
HEK293T cells were transfected 24 h after seeding in 12-well plates at a confluence of 372 
70%. Cells and supernatants were harvested 48 hours post-transfection. The 373 
pCMV-SPORT6 expression plasmids used for the screening of genes encoding proteins 374 
potentially harboring RNA binding domains listed in Supplementary Table 1 represent 375 
verified full-length cDNA Clones (Open Biosystems) obtained through the Mammalian 376 
Gene Collection (MGC). Regnase-1 and Roquin-1 expression plasmids have been 377 
described previously 39. The Roquin-2 expression plasmid was kindly provided by Dr. 378 
Hidenori Ichijo (The University of Tokyo). Replication competent HIV-1 particles were 379 
obtained by transfecting HEK293T cells with the following HIV-1 infectious plasmids: 380 




pNL4-3 (cat#114) 40 was obtained through the NIH AIDS Reagent Program. HIV-1 381 
clones pCH058 (cat#11856) 41 and pAD17 (cat#12423) 42 were obtained through the 382 
NIH AIDS Reagent Program from Dr. Beatrice Hahn (University of Pennsylvania). The 383 
SIVcpz molecular clone MB897 43, as well as HIV-1 pCH058 (6-month), pCH077 384 
(6-month), pCH440, pCH200v2, pCH534 and CH042 were kindly provided by Beatrice 385 
Hahn 44-46. The HIV-1 AD8 infectious molecular clone was obtained from Cathleen 386 
Collins (UCSD, San Diego) and has been described previously 47. The Moloney 387 
Leukemia Virus strain pMLV48 was kindly provided by Dr. Komano Atsushi (Nagoya 388 
Medical Center). The Human Foamy virus strain HSRV13 was kindly provided by David 389 
Russel (University of Washington). pCMV259 was kindly provided by Junichi Sakuragi 390 
(Osaka University)48. Forty eight hours post-transfection, culture supernatants were 391 
harvested, then filtrated, and stocked as a viral solution.  For the replication assay, empty 392 
vector or N4BP1 expressing Jurkat cells were seeded at 2 × 105 cells in 48 well plate. 393 
Then, they were inoculated with HIV-1 NL4-3. Primary CD4+ T cells were isolated from 394 
human blood from 3 healthy donors by Ficoll Paque gradient centrifugation and negative 395 
selection using the RosetteSepTM Human CD4+ T cell Enrichment cocktail (Stem Cell 396 
Technologies) and cultured in RPMI1640. Monocytes were separated from PBMCs by 397 
plastic adherence and differentiated into monocyte-derived macrophages (MDM) using 398 
AB-serum (10%) and macrophage colony stimulating factor (M-CSF, R&D Systems; 15 399 
ng/ml). Primary human macrophages were differentiated from human peripheral blood 400 
mononuclear cells from 3 healthy donors. PBMCs were seeded onto the plate in serum 401 
free RPMI-1640 for 3 hours at 37 °C. Non-adherent cells in the supernatants were 402 
discarded and adherent monocytes were cultured in RPMI-1640 with 10% FCS and 403 
M-CSF (15 ng/ml, PeproTech) for 6 days.  404 
 405 
Generation of Virus Stocks 406 
HEK293T cells were sown in 6-well plates and transfected with proviral HIV-1 DNA (5 407 




µg) at a confluence of 70-80 % using a standard calcium phosphate transfection 408 
protocol. For mock infection controls, HEK293T cells were treated with transfection 409 
reagents only. Supernatants were harvested 40 h post transfection. 410 
 411 
Infectivity Assay 412 
Infectious HIV-1 released into the cell culture supernatant was quantified by infection of 413 
TZM-bl reporter cells. Appropriate virus dilutions were added to 5 × 103 TZM-bl cells 414 
per well of a 96-well plate. The cells were harvested 48 hours post-infection, and a 415 
β-galactosidase assay was performed using the Galacto-Star Mammalian Reporter Gene 416 
Assay System (Applied Biosystems) according to the manufacturer’s protocol. 417 
Galactosidase activity was quantified as relative light units per second (RLU/s) using a 418 
1420 ALBOSX multilabel counter (Perkin Elmer). 419 
 420 
Plasmid Construction 421 
The cDNA of human N4BP1 was ligated into pFlag-CMV2 (Invitrogen), pEFs-Flag-SBP, 422 
or CSII-CMV-MCS-IRES2-Bsd for mammalian cell expression. The site-directed mutant 423 
expression vectors including pFlag-CMV2 N4BP1 D623N or R509A and pEFs-Flag-SBP 424 
D623N were generated using the Quick change lighting Site-Directed Mutagenesis Kit 425 
(Agilent). Deletion mutant cDNAs encoding amino acids 1-700 (Δ1), 1-600 (Δ2), 1-500 426 
(Δ3) and 1-400 (Δ4) of N4BP1 were inserted into the pFlag-CMV2 vector. A lentiviral 427 
packaging plasmid, CSII-CMV-MCS-IRES2-Bsd was provided by Dr. Miyoshi in Keio 428 
University. N4BP1 and its R509A mutant were inserted into the pInducer20, a Tet-on 429 
doxycycline-inducible lentiviral expression plasmid. 430 
 431 
Immunoblotting 432 
HEK293T cells were seeded in 12 well plates. Cell free viral solutions were pelleted by 433 
ultracentrifugation of the culture supernatants at 40,000 rpm for 1 hour at 4°C by using 434 




TL-100 (Beckman), and then lysed in the Immunoblot lysis buffer. Cell lysates were 435 
mixed with 3x loading sample buffer supplemented with 15% β-mercaptoethanol. Protein 436 
samples were resolved on a 5-20% NuPAGE gel (Invitrogen). Proteins were transferred 437 
from the SDS-PAGE gel to Immobilon-PVDF membranes (Merck Millipore). Proteins 438 
were labeled with antibodies against HIV-1 Env (1:2000; 16H3, Cat#12559, NIH AIDS 439 
Research and Reference Reagent program), p24 (1:2000, polyclonal; ViroStat), Vif 440 
(1:2000; #319; NIH AIDS Research and Reference Reagent program), Nef (1:2000; 441 
3D12, ThermoFisher), Vpr (1:2000; 8D1, Cosmo Bio), Vpu (1:2000; #969, NIH AIDS 442 
Research and Reference Reagent program), Flag (1:1000; monoclonal; F7425, Sigma, or 443 
polyclonal; F7425, Sigma), Mouse IgG Isotype Control (1:1000; #31903, 444 
ThermoFisher); β-Actin (1:1000; polyclonal; sc-1615, Santa Cruz), MALT1 (1:1000; 445 
#2494, Cell Signaling Technology), GAPDH (1:1000; sc-47724, Santa Cruz), α-Tubulin 446 
(1:1000; T9026, Sigma), IκBα (1:1000; C-21, Santa Cruz), GFP (1:1000; ab290, Abcam) 447 
and N4BP1 (1:2000, ab197079, Abcam). The anti-N4BP1 antibody recognizes the 448 
N-terminal portion of N4BP1 (aa 250-300). 449 
 450 
Drug Treatment 451 
Jurkat cells and THP-1 cells were stimulated with IFN-α (Sigma Aldrich, 1000 U/ml).  452 
Jurkat cells were stimulated with 50 ng/ml Phorbol 12-myristate 13-acetate (PMA: Sigma 453 
Aldrich) with or without 500 nM ionomycin (Sigma Aldrich). Human primary CD4+ T 454 
cells were stimulated with IFN-α subtypes (50 ng/ml)  (kindly provided by Kathrin 455 
Sutter, University Duisburg-Essen) or IL-27 (R&D Systems; Cat# 2526; 5 ng/ml) for 72 456 
hours, IFN-γ (SIGMA Aldrich; 50 ng/ml), IL-2 (Miltenyi Biotech; 100 U/ml) or 457 
anti-CD3/CD28 beads (Dynabeads Human T-Activator CD3/CD28, Gibco) for 24 hours. 458 
JNLGFP, J-Lat5A8 and J-Lat10.6 cells were stimulated with 10-50 ng/ml PMA for 24 459 
hours. zVRPR-fmk (Enzo Life Sciences), a MALT1 inhibitor, zVAD-fmk (R&D systems), 460 
a Pan-Caspase inhibitor and MG132 (Merck Millipore),proteasome inhibitor, were used 461 




at concentrations of 100 μM, 10 μM and 0.001-10 μM, respectively.  462 
 463 
RNA Isolation, RT and Quantitative RT-PCR 464 
Total RNA was isolated using Trizol reagent (Invitrogen). Reverse transcription was 465 
performed using ReverTra Ace (TOYOBO) according to the manufacturer’s instruction. 466 
The relative RNA expression levels of IFNB, 18S, N4BP1, tat/rev, vif, gag, HIV-1 total 467 
RNA, BST2, and ISG15, MLV gag, SIVcpz gag, HSRV13 gag and Influenza A segment 4 468 
(HA) were measured by SYBR Green Real-Time PCR in Applied Biosystems Step One 469 
Plus. Viral RNA in supernatants was extracted using the ZR viral RNA kit 470 
(ZymoResearch). The sequences of the primers used in qPCR are shown in 471 
Supplementary Table 2. 472 
 473 
Humanized Mice 474 
NOD.Cg-Prkdcscid Il2rgtm1Sug/Jic (NOD/SCID Il2rgnull) mice were obtained from the 475 
Central Institute for Experimental Animals (Kanagawa, Japan). The mice were 476 
maintained under specific-pathogen-free conditions and were handled in accordance with 477 
Regulations on Animal Experimentation at Kyoto University. The study protocol was 478 
approved by the Animal Experimentation Committee in Kyoto University. Human 479 
CD34+ hematopoietic stem cells (HSCs) were isolated from human fetal liver as 480 
previously described 49. To generate humanized mice (NOG-hCD34 mice), human fetal 481 
liver-derived CD34+ cells (5×104 to 12×104 cells) were intrahepatically injected into 482 
newborn NOG mice aged 0 to 2 days after X-irradiation (10 cGy per mouse) in an 483 
RX-650 X-ray cabinet system (Faxitron X-ray Corporation). Humanized mice were 484 
randomly assigned to HIV-1 infection or mock treatment. 485 
 486 
Generation of N4BP1 or MALT1 Knockout Cells by the CRISPR/Cas9 System 487 
N4BP1 knockout Jurkat cells were generated by transiently transfecting 488 




pX330-U6-Chimeric_BB-CBh-hSpCas9 plasmid (Addgene) with Neon Transfection 489 
System according to the manufacturer’s protocol. N4BP1 coding exon was targeted 490 
using the following sgRNA target site: 5’- AGATATAAAAGAAACTACTG -3’. Single 491 
clones were obtained by limiting dilution in 96-well U-bottomed culture plates. Control 492 
cells were obtained following transfection of the plasmid without sgRNA. For 493 
generating MALT1 knockout Jurkat cells, cells were delivered with the sgRNA and 494 
Cas9 expressing lentivirus vector (LentiCrispr v2 puro: Addgene) targeting the MALT1 495 
coding sequences; sgRNA1 5’-GCAGTGCATGTAAAAGATGC-3’, sgRNA2 496 
5’-ATTCAGCCAGTGGTCACAGC-3’. Control cells were obtained by transduction of 497 
lenticrispr v2 expressing non-targeting control sgRNA; 5’- 498 
GGCCGATAATGATCCGACCG -3. Two days after transduction, cells were cultured 499 
with 1μg/ml Puromycin for 10 days. Knockout of N4BP1 or MALT1 was examined by 500 
immunoblot analysis. 501 
 502 
Establishment of Stably N4BP1 Expressing Cells 503 
Stably N4BP1 expressing Jurkat cells were generated by transfection with CSII Bsd 504 
IRES MCS-N4BP1 using the Neon Transfection System. Three days after transfection, 505 
N4BP1 expressing cells were selected by culturing them in 10 μg/ml 506 
blasticidin-containing RPMI-1640 for 14 days. Control cells were prepared by 507 
transfecting an empty plasmid. In some experiments, single clones were obtained by 508 
limiting dilution in 96-well U-bottomed culture plates. Stably N4BP1 expressing 509 
HEK293T cells and control cells were generated by transfection with CSII Bsd IRES 510 
MCS-N4BP1 and empty plasmid, respectively. For inducible expression of N4BP1, 511 
N4BP1 KO cells, JNLGFP, N4BP1 KO JNLGFP or J-Lat10.6 cells were prepared by 512 
pseudotyped lentivirus vector transduction with pInducer20 vector with or without 513 
wild-type or R509A mutant N4BP1 followed by selection in G418. 514 
 515 




siRNA Transfection and Infection of Macrophages and Jurkat cells 516 
On days 7 and 10 of differentiation, MDM were transfected with N4BP1-specific or 517 
non-targeting control siRNA using Lipofectamine RNAiMAX (Life technologies) 518 
followed by infection at day 10. All siRNAs were provided in lyophilized state by 519 
ThermoFisher (#18638, #18639, #18640) or Eurofins Genomics (non-targeting control: 520 
UUCUCCGAACGUGUCCACGUdTdT) and suspended in nuclease-free water to reach 521 
a final concentration of 20 μM. siRNA transfection was performed in 12-well plates with 522 
three technical replicates for each sample. For one well, 2.25 μl siRNA were mixed with 523 
150 μl Opti-MEM and 6 μl Lipofectamine RNAiMAX were mixed with 150 μl 524 
Opti-MEM. These two solutions were then mixed and incubated at room temperature for 525 
10 min. Afterwards, 300 μl of the mixture was dropped on the well containing 1 ml of cell 526 
culture medium. Medium was changed 18 h after each transfection. 3 and 6 days post 527 
infection, macrophage culture supernatants were harvested and used to infect TZM-bl 528 
reporter cells. To this end, 6,000 TZM-bl cells were sown in 96-well plates and infected 529 
in triplicate with cell culture supernatants containing infectious virus. Three days later, 530 
infection rates were determined using a galactosidase screen kit (GalScreen-Applied 531 
Bioscience) according to the manufacturer’s instructions. β-galactosidase activities were 532 
quantified as relative light units per second (RLU/s) using an Orion Microplate 533 
Luminometer. For knockdown in Jurkat cells, cells were transfected with N4BP1-specific 534 
siRNA (s18640) or negative control siRNA using NEON according to the manufacturer’s 535 
protocol. Differentiated human macrophages were transfected with siRNA on days 6 and 536 
8 after isolation. Cells were transfected with N4BP1-specific siRNA (s18638-18640) or 537 
negative control siRNA using Lipofectamin RNAiMAX (Life technologies) according to 538 
the manufacturer’s instructions.  539 
 540 
Structure Modeling. 541 
The PIN RNase domain of human N4BP1 was modeled with the SFAS threading meta 542 




server (http://sysimm.ifrec.osaka-u.ac.jp/sfas2/) using human Regnase-1 (PDB Identifier 543 
3v32, chain B) as a template. The conservation heatmap was constructed by aligning the 544 
top 1000 hits from the NCBI nr database to human N4BP1 using MAFFT (PMID: 545 
23329690), and computing the sequence identity to human N4BP1. The sequence identity 546 
was expressed as a temperature factor in the human N4BP1 model PDB file and displayed 547 
in PyMOL (The PyMOL Molecular Graphics System, Version 1.8 Schrödinger, LLC.).  548 
 549 
Generation of Recombinant N4BP1 and N4BP1-D623N Proteins 550 
HEK293T cells were transfected with pEFs_Flag-SBP-N4BP1 or 551 
pEFs_Flag-SBP-N4BP1-D623N using polyethyleneimine “MAX” (Polysciences). Three 552 
days after transfection, cells were lysed in NF-lysis buffer [20 mM Tris (pH 7.5), 150 mM 553 
NaCl, 0.25 M Sucrose, 0.5% (v/v) NP-40, 1% (v/v) Tween 20] containing 1 mM DTT, 554 
protease inhibitor cocktail (Nacalai Tesque), phosphatase inhibitor cocktail (EDTA free) 555 
(Nacalai Tesque) and 50 μg/ml RNase A. SBP-tagged proteins were captured by 556 
Streptavidin Mag Sepharose (GE Healthcare) and eluted with T buffer (20 mM HEPES 557 
(pH 7.5), 150 mM NaCl, 2.5 mM MgCl2, 0.05% (v/v) Tween 20) containing 1 mM DTT, 558 
0.1 x protease inhibitor cocktail (EDTA free) (Nacalai Tesque), 0.1 x phosphatase 559 
inhibitor cocktail (Nacalai Tesque) and 2 mM d-desthiobiotin (Sigma-Aldrich).  560 
 561 
In vitro RNA Cleavage Assay 562 
The in vitro RNA cleavage assay has been previously described 39. Briefly, recombinant 563 
N4BP1 protein and in vitro transcribed 5′-[32P]-labelled viral RNA (tat, rev and nef 564 
subgenomic RNA of HIV-1 NL4-3) 50 or a 513 base RNA fragment from the 565 
pBluescript® vector) were mixed in cleavage buffer (25 mM HEPES, 50 mM potassium 566 
acetate, 5 mM DTT, 5 mM magnesium acetate and 0.2 U/ml RNasin (Promega)) for 60 567 
min at 37 degrees. The cleaved RNA was analyzed by denaturing 6% 568 
polyacrylamide-TBE-urea gels (Invitrogen) and autoradiography. The sequence used for 569 




in vitro transcription and the in vitro cleavage assay is shown in Supplementary Table 3. 570 
 571 
Northern Blotting.  572 
Using Trizol reagent, total RNA was isolated from HEK293T cells 48 hours 573 
post-transfection with pNL4-3 together with N4BP1 expression plasmid, D623N or 574 
empty plasmid. Extracted RNA was electrophoretically separated, transferred to 575 
Hybond-N+ (GE healthcare), and hybridized with the probe derived from a fragment of 576 
pNL4-3. 32P-labeled probe was generated from the 422-nt XhoI/BamHI restriction 577 
fragment in the 3’ UTR of pNL4-3, which is present in all HIV-1 mRNAs. HIV-1 primary 578 
RNA transcripts, generated by alternative splicing, were detected as three major bands 579 
representing three different sizes. 580 
 581 
RNA-Immunoprecipitation and qPCR Analysis 582 
HEK293T cells seeded at 3 × 106 in 10 cm plates were transfected with 5 μg of pNL4-3 583 
together with 5 μg of a plasmid expressing the N4BP1 D623N mutant. Flag-tagged 584 
N4BP1 was immunoprecipitated with an anti-Flag antibody (Sigma) or control mouse 585 
IgG isotype controls (Thermo Fisher) 48 hours after transfection. N4BP1 interacting 586 
HIV-1 RNA was extracted using Trizol, quantified by RT-qPCR and normalized to 18S 587 
RNA bound in a non-specific manner.  588 
 589 
Analysis of Global Protein Synthesis 590 
Control and N4BP1 KO Jurkat cells were cultured for 1 day. As negative control, some 591 
control cells were treated with a protein synthesis inhibitor, Cycloheximide (Cayman 592 
Chemical) for 30 min. Then the cells were harvested, and translating polypeptides were 593 
labeled with O-Propargyl-Puromycin (OPP) for 30 min at 37 °C followed by staining 594 
with 5 FAM Azide using the Protein Synthesis Assay kit (Cayman Chemical) according 595 
to the manufacturer’s instruction. The cells were analyzed by Flow cytometry 596 




(FACSVerse; BD). The data analysis was performed using FlowJo (LCC). 597 
 598 
HIV-LTR Reporter Gene Assay. 599 
TZM-bl cells cells were transfected with pGL3-HIV-LTR-Luc plasmid or pGL3-empty 600 
plasmid together with N4BP1 expression plasmid or empty control plasmid. 24 h 601 
post-transfection, cells were lysed and luciferase activities in the lysates were determined 602 
using the Dual-luciferase reporter assay system (Promega).  603 
 604 
Detection of Early RT products, Late RT product and Integrated Proviral DNA 605 
Quantification of HIV-1 early RT (R/U5), late RT (U5/gag) and integrated products by 606 
real-time PCR was done by following a published protocol (Suzuki et al., 2003). Briefly, 607 
virus was treated with DNase-I (TAKARA) at a concentration of 20 mg/ml in the 608 
presence of 10mM MgCl2 at the room temperature. Heat-inactivated (65°C, 30 min) 609 
virus was used as a negative control for infection. Jurkat cells were transfected with 610 
N4BP1 or control siRNA. One day after transfection, Jurkat cells were exposed to 611 
HIV-1 NL4-3 (MOI 0.1) or heat inactivated HIV-1 at 37°C for 2 hours. Total DNA was 612 
isolated 12 hours after infection, by using DNeasy Blood & Tissue Kits (QIAGEN) 613 
according to the manufacturer’s instructions. Early RT products, late RT products and 614 
integrated DNA were quantified by real-time PCR as described previously (Suzuki et al., 615 
2003). 616 
 617 
Influenza Infection Experiment 618 
HEK293T cells stably expressing N4BP1 or control plasmid were infected with 619 
Influenza A virus PR8 or WSN strain for 24 hours before total RNA or culture media 620 
were harvested. Total RNA was subjected to qPCR analysis to measure the expression 621 
levels of viral mRNA for segment 4 (HA). The viral growth in the culture media was 622 
titrated by using plaque assays on Madin–Darby canine kidney (MDCK) cells. 623 





Statistical Analysis and Reproducibility. 625 
Statistical analyses were conducted using Prism 8 (GraphPad, La Jolla, CA, USA) or 626 
Excel for Office365. Statistical significance was calculated with an unpaired two-tailed 627 
Student’s t-test. Data are presented as the mean ± s.d.. A P value of < 0.05 was considered 628 
statistically significant. The screening of RBPs restricting HIV-1 was repeated and the 629 
results were confirmed in an independent experiment (Fig. 1a). The in vivo experiment 630 
with humanized mice (Fig. 2e) was performed once. The data for HIV-1 yield in MDM 631 
treated with N4BP1-specific siRNAs (Fig. 3g) and p24 production comparing between 632 
WT or R509A mutant N4BP1 reconstituted JNLGFP cells (Fig. 6h) are pooled from 633 
three independent experiments. Other In vitro experiments were representative of 2-5 634 
independent experiments with similar results. 635 
 636 
Data Availability 637 
The data that support the findings of this study are available from the corresponding 638 
author upon request. 639 
 640 
 641 
  642 





We thank all colleagues in our laboratory for helpful discussion, M. Tsuji and J. 644 
Hasegawa for secretarial assistance, as well as R. Linsenmeyer and J. A. van der Merwe 645 
for excellent technical assistance. We thank Kathrin Sutter (University of 646 
Duisburg-Essen, Germany) for providing IFNα subtypes and Cathleen Collins (UCSD, 647 
USA), Beatrice Hahn (University of Pennsylvania, USA), Warner C. Greene (Gladstone 648 
Institute for Virology and immunology, USA), David N. Levy (New York University of 649 
Dentistry), Hung Fan (UC Irvine, USA) and David Russell (University of Washington, 650 
USA) for providing plasmids. This work was supported by the Agency for Medical 651 
Research and Development (AMED) under Grant Numbers JP16gm0410017 (to O.T.), 652 
18fk0410014h0001 (to O.T.), JP18fm0208006h002 (to K.S.), JP18fk0410019h0001 (to 653 
K.S.) and JP18fk0410014h0001 (to Y.K.); the Japan Society for the Promotion of 654 
Science (JSPS) KAKENHI Grant Number 18H05278 (to O.T.), 16H06429 (to K.S.), 655 
16K21723 (to K.S.), and 17H05813 (to K.S.), and 18H02662 (to K.S.), Joint 656 
Usage/Research Center Program of Institute for Frontier Life and Medical Sciences 657 
Kyoto University (to O.T., K.S. and Y.K.); and Core-to-Core Program. This work was 658 
also supported by grants from Takeda Science Foundation and The Uehara Memorial 659 
Foundation (to O.T.). D.S. was supported by the DFG priority program “Innate Sensing 660 
and Restriction of Retroviruses” (SPP 1923) and the junior professorship programme of 661 
the state Baden-Wuerttemberg. FK is also supported by SPP 1923, DFG CRC 1279 and 662 
an Advanced ERC grant (Anti-Virome).  663 
 664 
Author Contributions 665 
D.Y., K.S., D.S. and O.T. designed the study. D.Y. designed, carried out and analyzed 666 
experiments. T.I., T.I., L.K., S.J., E.R., D.H., N.M, K.A, T.U and T.M. provided 667 
technical and intellectual assistance. S.M. and T.N. conducted influenza infection 668 
experiments. A.Y. provided recombinant proteins. D.S. performed structural modeling 669 




and bioinformatic analysis. D.Y., D.S. and O.T. wrote the manuscript. K.S, F.K., Y.K. 670 
and O.T. supervised the study. 671 
 672 
Competing interests 673 
The authors declare no competing financial interests. 674 
 675 
  676 





1 Simon, V., Bloch, N. & Landau, N. R. Intrinsic host restrictions to HIV-1 and 678 
mechanisms of viral escape. Nat Immunol 16, 546-553, doi:10.1038/ni.3156 (2015). 679 
2 Krapp, C. et al. Guanylate Binding Protein (GBP) 5 Is an Interferon-Inducible 680 
Inhibitor of HIV-1 Infectivity. Cell Host Microbe 19, 504-514, 681 
doi:10.1016/j.chom.2016.02.019 (2016). 682 
3 Goujon, C. et al. Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 683 
infection. Nature 502, 559-562, doi:10.1038/nature12542 (2013). 684 
4 Kane, M. et al. MX2 is an interferon-induced inhibitor of HIV-1 infection. Nature 502, 685 
563-566, doi:10.1038/nature12653 (2013). 686 
5 Liu, Z. et al. The interferon-inducible MxB protein inhibits HIV-1 infection. Cell 687 
Host Microbe 14, 398-410, doi:10.1016/j.chom.2013.08.015 (2013). 688 
6 Stremlau, M. et al. The cytoplasmic body component TRIM5alpha restricts HIV-1 689 
infection in Old World monkeys. Nature 427, 848-853, doi:10.1038/nature02343 690 
(2004). 691 
7 Neil, S. J., Zang, T. & Bieniasz, P. D. Tetherin inhibits retrovirus release and is 692 
antagonized by HIV-1 Vpu. Nature 451, 425-430, doi:10.1038/nature06553 (2008). 693 
8 Van Damme, N. et al. The interferon-induced protein BST-2 restricts HIV-1 release 694 
and is downregulated from the cell surface by the viral Vpu protein. Cell Host 695 
Microbe 3, 245-252, doi:10.1016/j.chom.2008.03.001 (2008). 696 
9 Hrecka, K. et al. Vpx relieves inhibition of HIV-1 infection of macrophages mediated 697 
by the SAMHD1 protein. Nature 474, 658-661, doi:10.1038/nature10195 (2011). 698 
10 Laguette, N. et al. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 699 
restriction factor counteracted by Vpx. Nature 474, 654-657, 700 
doi:10.1038/nature10117 (2011). 701 
11 Doyle, T., Goujon, C. & Malim, M. H. HIV-1 and interferons: who's interfering with 702 
whom? Nat Rev Microbiol 13, 403-413, doi:10.1038/nrmicro3449 (2015). 703 
12 Shaw, A. E. et al. Fundamental properties of the mammalian innate immune system 704 
revealed by multispecies comparison of type I interferon responses. PLoS Biol 15, 705 
e2004086, doi:10.1371/journal.pbio.2004086 (2017). 706 
13 Carpenter, S., Ricci, E. P., Mercier, B. C., Moore, M. J. & Fitzgerald, K. A. 707 
Post-transcriptional regulation of gene expression in innate immunity. Nat Rev 708 
Immunol 14, 361-376, doi:10.1038/nri3682 (2014). 709 
14 Mino, T. & Takeuchi, O. Post-transcriptional regulation of cytokine mRNA controls 710 
the initiation and resolution of inflammation. Biotechnol Genet Eng Rev 29, 49-60, 711 
doi:10.1080/02648725.2013.801236 (2013). 712 




15 Gao, G., Guo, X. & Goff, S. P. Inhibition of retroviral RNA production by ZAP, a 713 
CCCH-type zinc finger protein. Science 297, 1703-1706, doi:10.1126/science.1074276 714 
(2002). 715 
16 Zhu, Y. et al. Zinc-finger antiviral protein inhibits HIV-1 infection by selectively 716 
targeting multiply spliced viral mRNAs for degradation. Proc Natl Acad Sci U S A 717 
108, 15834-15839, doi:10.1073/pnas.1101676108 (2011). 718 
17 Takata, M. A. et al. CG dinucleotide suppression enables antiviral defence targeting 719 
non-self RNA. Nature 550, 124-127, doi:10.1038/nature24039 (2017). 720 
18 Goldstone, D. C. et al. HIV-1 restriction factor SAMHD1 is a deoxynucleoside 721 
triphosphate triphosphohydrolase. Nature 480, 379-382, doi:10.1038/nature10623 722 
(2011). 723 
19 Liu, S. et al. MCPIP1 restricts HIV infection and is rapidly degraded in activated 724 
CD4+ T cells. Proc Natl Acad Sci U S A 110, 19083-19088, 725 
doi:10.1073/pnas.1316208110 (2013). 726 
20 Gerstberger, S., Hafner, M. & Tuschl, T. A census of human RNA-binding proteins. 727 
Nat Rev Genet 15, 829-845, doi:10.1038/nrg3813 (2014). 728 
21 Castello, A. et al. Insights into RNA Biology from an Atlas of Mammalian 729 
mRNA-Binding Proteins. Cell 149, 1393-1406, doi:10.1016/j.cell.2012.04.031 (2012). 730 
22 Baldauf, H. M. et al. SAMHD1 restricts HIV-1 infection in resting CD4(+) T cells. 731 
Nat Med 18, 1682-1687, doi:10.1038/nm.2964 (2012). 732 
23 Descours, B. et al. SAMHD1 restricts HIV-1 reverse transcription in quiescent 733 
CD4(+) T-cells. Retrovirology 9, 87, doi:10.1186/1742-4690-9-87 (2012). 734 
24 Murillas, R., Simms, K. S., Hatakeyama, S., Weissman, A. M. & Kuehn, M. R. 735 
Identification of developmentally expressed proteins that functionally interact with 736 
Nedd4 ubiquitin ligase. J Biol Chem 277, 2897-2907, doi:10.1074/jbc.M110047200 737 
(2002). 738 
25 Sharma, P., Murillas, R., Zhang, H. & Kuehn, M. R. N4BP1 is a newly identified 739 
nucleolar protein that undergoes SUMO-regulated polyubiquitylation and 740 
proteasomal turnover at promyelocytic leukemia nuclear bodies. J Cell Sci 123, 741 
1227-1234, doi:10.1242/jcs.060160 (2010). 742 
26 Marco, A. & Marin, I. CGIN1: a retroviral contribution to mammalian genomes. Mol 743 
Biol Evol 26, 2167-2170, doi:10.1093/molbev/msp127 (2009). 744 
27 Thome, M. Multifunctional roles for MALT1 in T-cell activation. Nat Rev Immunol 8, 745 
495-500, doi:10.1038/nri2338 (2008). 746 
28 Uehata, T. et al. Malt1-induced cleavage of regnase-1 in CD4(+) helper T cells 747 
regulates immune activation. Cell 153, 1036-1049, doi:10.1016/j.cell.2013.04.034 748 





29 Jeltsch, K. M. et al. Cleavage of roquin and regnase-1 by the paracaspase MALT1 750 
releases their cooperatively repressed targets to promote T(H)17 differentiation. Nat 751 
Immunol 15, 1079-1089, doi:10.1038/ni.3008 (2014). 752 
30 Jordan, A., Bisgrove, D. & Verdin, E. HIV reproducibly establishes a latent infection 753 
after acute infection of T cells in vitro. EMBO J 22, 1868-1877, 754 
doi:10.1093/emboj/cdg188 (2003). 755 
31 Kutsch, O., Benveniste, E. N., Shaw, G. M. & Levy, D. N. Direct and quantitative 756 
single-cell analysis of human immunodeficiency virus type 1 reactivation from 757 
latency. J Virol 76, 8776-8786 (2002). 758 
32 Chan, J. K., Bhattacharyya, D., Lassen, K. G., Ruelas, D. & Greene, W. C. 759 
Calcium/calcineurin synergizes with prostratin to promote NF-kappaB dependent 760 
activation of latent HIV. PLoS One 8, e77749, doi:10.1371/journal.pone.0077749 761 
(2013). 762 
33 Li, H., He, H., Gong, L., Fu, M. & Wang, T. T. Short Communication: Preferential 763 
Killing of HIV Latently Infected CD4(+) T Cells by MALT1 Inhibitor. AIDS Res Hum 764 
Retroviruses 32, 174-177, doi:10.1089/AID.2015.0343 (2016). 765 
34 Michienzi, A., Cagnon, L., Bahner, I. & Rossi, J. J. Ribozyme-mediated inhibition of 766 
HIV 1 suggests nucleolar trafficking of HIV-1 RNA. Proc Natl Acad Sci U S A 97, 767 
8955-8960 (2000). 768 
35 Lusic, M. et al. Proximity to PML Nuclear Bodies Regulates HIV-1 Latency in 769 
CD4+T Cells. Cell Host & Microbe 13, 665-677, doi:10.1016/j.chom.2013.05.006 770 
(2013). 771 
36 Nakagawa, M. et al. MALT1 contains nuclear export signals and regulates 772 
cytoplasmic localization of BCL10. Blood 106, 4210-4216, 773 
doi:10.1182/blood-2004-12-4785 (2005). 774 
37 Fu, M. & Blackshear, P. J. RNA-binding proteins in immune regulation: a focus on 775 
CCCH zinc finger proteins. Nat Rev Immunol 17, 130-143, doi:10.1038/nri.2016.129 776 
(2017). 777 
38 Takeuchi, O. Endonuclease Regnase-1/Monocyte chemotactic protein-1-induced 778 
protein-1 (MCPIP1) in controlling immune responses and beyond. Wiley Interdiscip 779 
Rev RNA 9, doi:10.1002/wrna.1449 (2018). 780 
39 Mino, T. et al. Regnase-1 and Roquin Regulate a Common Element in Inflammatory 781 
mRNAs by Spatiotemporally Distinct Mechanisms. Cell 161, 1058-1073, 782 
doi:10.1016/j.cell.2015.04.029 (2015). 783 
40 Adachi, A. et al. Production of acquired immunodeficiency syndrome-associated 784 




retrovirus in human and nonhuman cells transfected with an infectious molecular 785 
clone. J Virol 59, 284-291 (1986). 786 
41 Salazar-Gonzalez, J. F. et al. Genetic identity, biological phenotype, and evolutionary 787 
pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp 788 
Med 206, 1273-1289, doi:10.1084/jem.20090378 (2009). 789 
42 Salazar-Gonzalez, J. F. et al. Deciphering human immunodeficiency virus type 1 790 
transmission and early envelope diversification by single-genome amplification and 791 
sequencing. J Virol 82, 3952-3970, doi:10.1128/JVI.02660-07 (2008). 792 
43 Van Heuverswyn, F. et al. Genetic diversity and phylogeographic clustering of 793 
SIVcpzPtt in wild chimpanzees in Cameroon. Virology 368, 155-171, 794 
doi:10.1016/j.virol.2007.06.018 (2007). 795 
44 Fenton-May, A. E. et al. Relative resistance of HIV-1 founder viruses to control by 796 
interferon-alpha. Retrovirology 10, 146, doi:10.1186/1742-4690-10-146 (2013). 797 
45 Parrish, N. F. et al. Phenotypic properties of transmitted founder HIV-1. Proc Natl 798 
Acad Sci U S A 110, 6626-6633, doi:10.1073/pnas.1304288110 (2013). 799 
46 Parrish, N. F. et al. Transmitted/Founder and Chronic Subtype C HIV-1 Use CD4 800 
and CCR5 Receptors with Equal Efficiency and Are Not Inhibited by Blocking the 801 
Integrin alpha 4 beta 7. Plos Pathogens 8, doi:ARTN e1002686 802 
10.1371/journal.ppat.1002686 (2012). 803 
47 Mashiba, M., Collins, D. R., Terry, V. H. & Collins, K. L. Vpr overcomes 804 
macrophage-specific restriction of HIV-1 Env expression and virion production. Cell 805 
Host Microbe 16, 722-735, doi:10.1016/j.chom.2014.10.014 (2014). 806 
48 McBride, M. S. & Panganiban, A. T. The human immunodeficiency virus type 1 807 
encapsidation site is a multipartite RNA element composed of functional hairpin 808 
structures. J Virol 70, 2963-2973 (1996). 809 
49 Nakano, Y. et al. HIV-1 competition experiments in humanized mice show that 810 
APOBEC3H imposes selective pressure and promotes virus adaptation. PLoS 811 
Pathog 13, e1006348, doi:10.1371/journal.ppat.1006348 (2017). 812 
50 Gringhuis, S. I. et al. HIV-1 blocks the signaling adaptor MAVS to evade antiviral 813 
host defense after sensing of abortive HIV-1 RNA by the host helicase DDX3. Nat 814 
Immunol 18, 225-235, doi:10.1038/ni.3647 (2017). 815 
 816 
  817 




Figure Legends 818 
Fig. 1. Identification of N4BP1 as an antiretroviral restriction factor. 819 
a, HEK293T cells were co-transfected with pNL4-3 and one of 62 expression plasmids 820 
(Supplementary Table 1) encoding putative RNA binding proteins. Forty-eight hours post 821 
transfection, cell culture supernatants were harvested and used to infect TZM-bl reporter 822 
cells to determine infectious virus yield. The data values of two technical replicates.  823 
b, HEK293T cells were transfected with either pNL4-3 or pAD17 together with 824 
increasing amounts of N4BP1 expression plasmid. Expression of HIV-1 Env and Gag, 825 
and N4BP1 in cell lysates as well as Gag p24 in the culture supernatants was determined 826 
by immunoblot analysis 48 hours post-transfection. β-Actin was used as the loading 827 
control. The upper panel shows infectious virus yield relative to the empty vector control 828 
determined by the TZM-bl reporter assay. n = 3 biological replicates. Individual points 829 
and means ± s.d. are shown.  830 
c, HEK293T cells were co-transfected with proviral clones of HIV-1 together with 831 
increasing amounts of vector expressing N4BP1. 48 hours post-transfection, a TZM-bl 832 
reporter assay was performed to measure the production of infectious virus in 833 
supernatants. Infectious virus yield relative to the empty vector control is shown as mean 834 
± s.d of biological replicates (n = 3). TF, transmitted founder virus; CC chronic control 835 
virus; 6-mo, virus isolated 6 months post infection.  836 
P values were calculated using unpaired two-tailed Student’s t-test. *P < 0.05; ***P < 837 
0.005. 838 
 839 
Fig. 2. N4BP1 is upregulated upon IFN stimulation and restricts viral replication in 840 
T cells. 841 
a, N4BP1 mRNA levels were measured by RT-qPCR in Jurkat cells treated with IFN-α 842 
from human leukocytes (1000 U/ml) for the indicated periods of time. Data are shown as 843 
mean ± s.d. of biological replicates (n = 3). 844 




b, Immunoblot analysis of N4BP1 in cell lysates from Jurkat cells treated with IFN-α  845 
for 48 hours. β-Actin was used as the loading control. 846 
c, N4BP1 mRNA levels were measured by RT-qPCR in primary human CD4+ T cells 847 
treated with IFN-α for 24 h. Individual points and means ± s.d. are shown (n = 3). *P < 848 
0.05; ***P < 0.005.  849 
d, Expression levels of IFNB1, N4BP1, BST-2 and ISG15 mRNAs were measured by 850 
qPCR in Jurkat cells infected with HIV-1 NL4-3 (MOI 0.01). Data are shown as mean ± 851 
s.d. of biological replicates (n = 3).  852 
e, N4BP1 mRNA levels in spleens from humanized mice 6 weeks after HIV-1 infection (n 853 
= 8) or mock treatment (n = 6).  854 
f, Immunoblot analysis of N4BP1 in cell lysates from control and N4BP1-knockout 855 
Jurkat cells (left panel). N.S. Non-specific. Replication of HIV-1 NL4-3 (MOI 0.01) in 856 
N4BP1 knockout or control Jurkat cell lines (right panel). Infectivity of HIV-1 in the 857 
culture supernatants was measured by TZM-bl assay.  858 
g, Immunoblot analysis of N4BP1 in cell lysates from control cells and N4BP1-knockout 859 
Jurkat cells inducibly reconstituted with N4BP1 by using the Tet-on system and 860 
doxycycline stimulation (Dox) for 24 hours (left panel). Replication of HIV-1 NL4-3 861 
(MOI 0.01) in control or N4BP1 knockout Jurkat cell lines reconstituted with or without 862 
N4BP1 by Dox treatment (right panel). Infectivity of HIV-1 in the culture supernatants 863 
was measured by TZM-bl assay.  864 
h, Immunoblot analysis of Jurkat cells stably expressing FLAG-tagged N4BP1 (left 865 
panel). Replication of HIV-1 NL4-3 (MOI 0.01 or 0.001) in FLAG-N4BP1 expressing or 866 
control Jurkat cell lines (right panel). Infectivity of HIV-1 in the culture supernatants was 867 
measured by TZM-bl assay.  868 
P values were calculated using unpaired two-tailed Student’s t-test. *P < 0.05; **P < 0.01; 869 
***P < 0.005. 870 
 871 




Fig. 3. N4BP1 is upregulated upon IFN stimulation and restricts HIV-1 infection in 872 
macrophages 873 
a, Expression levels of N4BP1 or BST-2 mRNA were measured by RT-qPCR in 874 
macrophage-like THP-1 cells stimulated with IFN-α for the indicated periods of time. 875 
Data are shown as mean ± s.d. of biological replicates (n = 3).  876 
b, Immunoblot analysis of N4BP1 and β-Actin in cell lysates from macrophage-like 877 
THP-1 cells stimulated with IFN-α for 48 hours. 878 
c, Expression levels of N4BP1 mRNA were measured by RT-qPCR in human primary 879 
MDMs stimulated with IFN-α for 24 hours. n = 3 biological replicates. Individual points 880 
and means ± s.d. are shown.  881 
d, Expression levels of N4BP1 in human primary MDMs upon stimulation of IFN-α  for 882 
48 hours were determined by immunoblotting. 883 
e, N4BP1 expression levels were normalized to β-Actin levels and the unstimulated 884 
sample was set to 100 %. n = 3 biological replicates. Individual points and means ± s.d. 885 
are shown.  886 
f, Representative immunoblot analysis of human MDMs transfected with control siRNA 887 
or three different N4BP1-specific siRNAs (left panel). N4BP1 expression levels were 888 
normalized to β-Actin levels and the control siRNA sample was set to 100 %. Data are 889 
shown as mean values ± s.d. of 5 independent experiments.  890 
g, Human MDMs treated with control or N4BP1-specific siRNA (#18638-#18640) were 891 
infected with HIV-1 AD8 and analyzed for infectious virus production 3 (n = 9) and 6 (n = 892 
7) days post-infection (dpi). Shown are mean percentages ±s.d. relative to those detected 893 
in control cells (100%). 894 
P values were calculated using unpaired two-tailed Student’s t-test. *P < 0.05; **P < 0.01; 895 
***P < 0.005. 896 
 897 
Fig. 4. N4BP1 is a cellular RNase degrading HIV-1 RNA 898 




a, The expression levels of viral mRNA were measured by RT-qPCR in HEK293T cells 899 
cotransfected with an N4BP1 expression plasmid or an empty vector control together 900 
with the indicated viral infectious clones. n = 3 biological replicates. Individual points 901 
and means ± s.d. are shown. 902 
b, Domain architecture of human N4BP1.  903 
c, A structural modeling of the RNase domain of N4BP1. Colors highlight the 904 
evolutionary conservation of amino acids. D623, D704, D705 and D723 forming the 905 
catalytic center of the RNase are indicated (Left panel). Amino acid sequence alignment 906 
of the partial RNase domain of N4BP1 orthologs from various species. “*”Fully 907 
conserved residue, “:”conservation between groups of strongly similar properties, “.” 908 
conservation between groups of weakly similar properties (right panel). 909 
d, Purified N4BP1, but not its D623N mutant, cleaves [32P]-labeled RNA derived from a 910 
subgenomic sequence of HIV-1 NL4-3 in vitro.  911 
e, Structural models of the RNase domains (residues 616-775) in WT and D623N human 912 
N4BP1. 913 
f, Northern blot analysis of HIV viral RNAs in HEK293T cells co-transfected with 914 
pNL4-3 and vectors expressing N4BP1 or N4BP1 D623N. Ribosomal 28S and 18S 915 
RNAs were included as loading controls.  916 
g, RNA-IP-qPCR assay in HEK293T cells transfected with pNL4-3 together with or 917 
without Flag-tagged N4BP1. Flag-tagged N4BP1 D623N was immunoprecipitated with 918 
anti-Flab Ab or control IgG 48 hours after transfection and co-precipitated RNAs were 919 
quantified by RT-qPCR. n = 3 biological replicates. Individual points and means ± s.d. are 920 
shown.  921 
h, HEK293T cells were cotransfected with pNL4-3 and vectors expressing N4BP1 or 922 
N4BP1 D623N. Shown are the immunoblots of cellular extracts and viral particles in the 923 
culture supernatants.  924 
i, Infectious virus yield of HIV-1 NL4-3 in HEK293T cells transfected with pNL4-3 925 




together with expression plasmids for N4BP1 WT, N4BP1 D623N or an empty vector 926 
control as assessed by TZM-bl reporter assay. Infectious virus yield relative to the empty 927 
vector control is shown. n = 3 biological replicates. Individual points and means ± s.d. are 928 
shown.  929 
P values were calculated using unpaired two-tailed Student’s t-test. *P < 0.05, **P < 930 
0.001, ***P < 0.005. 931 
 932 
Fig. 5. TCR stimulation induces MALT1-mediated degradation of N4BP1  933 
a, Immunoblot analysis of N4BP1 levels in primary CD4+ T cells treated with 934 
IFN-γ (50 ng/ml), IL-2 (100 U/ml), PMA (50 ng/ml) plus ionomycin (500 nM) or 935 
anti-CD3/CD28 antibody-coated beads for 24 hours. 936 
b, N4BP1 protein levels in Jurkat cells stimulated with PMA plus ionomycin for the 937 
indicated periods of time were determined by immunoblotting.  938 
c, Immunoblot analysis of N4BP1 in parental or MALT1-deficient Jurkat cells stimulated 939 
with PMA plus ionomycin for 1 hour. 940 
d, N4BP1 protein levels in Jurkat cells stimulated with PMA plus ionomycin for 1 hour 941 
with zVAD-fmk, a pan-caspase inhibitor (10 μM) or zVRPR-fmk, a MALT1 inhibitor 942 
(100 μM). 943 
e, Schematic representations of N4BP1 and its mutants. The epitope of the 944 
N4BP1-specific antibody used in the present study is indicated. 945 
f, The apparent molecular weight of N4BP1 and its truncation mutants was determined by 946 
immunoblotting of transfected HEK293T cells. 947 
g, Sequence-logo plot representing the amino acid frequencies at positions P4 to P3’ in 16 948 
previously identified MALT1 cleavage sites (Supplementary Fig. 10e). 949 
h, Localization of the potential MALT1 cleavage site in N4BP1. Multiple sequence 950 
alignment of different N4BP1 orthologs . “*”Fully conserved residue, “.” conservation 951 
between groups of weakly similar properties. 952 




i, Cleavage of N4BP1 in HEK293T cells transfected with the indicated N-terminally 953 
Flag-tagged N4BP1 variants. Degradation of N4BP1 and emergence of the 72 kDa 954 
cleavage product were monitored by immunoblot with an anti-Flag antibody.  955 
j, N4BP1 levels were determined by immunoblotting of Jurkat cells transfected with an 956 
empty vector or expression plasmids for Flag-N4BP1.  957 
k, HEK293T cells were co-transfected with pNL4-3 and vectors expressing WT or 958 
mutant N4BP1. 48 hours post-transfection, a TZM-bl reporter assay was performed. 959 
Infectious virus yield relative to the empty vector control is shown. n = 3 biological 960 
replicates. Individual points and means ± s.d. are shown.  961 
P values were calculated using unpaired two-tailed Student’s t-test. ***P < 0.005.  962 
 963 
Fig. 6. MALT1-mediated degradation of N4BP1 in latently HIV-1 infected cells 964 
contributes to viral reactivation.   965 
a-b, Immunoblot analysis of N4BP1 and MALT1 in cell lysates from MALT1-deficient 966 
J-Lat10.6 (a), JNLGFP (b) or control cells stimulated with or without PMA (50 ng/ml) for 967 
24 hours.  968 
c-d, The expression levels of tat/rev and gag mRNA were quantified by qPCR in 969 
MALT1-deficient J-Lat10.6 (c) or JNLGFP cells (d) stimulated with PMA (50 ng/ml) for 970 
the indicated periods of time. Data are shown as mean ± s.d. of biological replicates (n = 971 
3).  972 
e-f, Immunoblot analysis of N4BP1 and Gag p24 proteins in cell lysates or culture 973 
supernatants from J-Lat10.6 (e) or JNLGFP cells (f), which inducibly express N4BP1 or 974 
N4BP1 R509A by the Tet-on system treating with Dox and were stimulated with PMA 975 
(10 ng/ml) for 24 hours. The levels of Gag p24 in the supernatants were quantified and 976 
indicated as the percentage of Dox (-) controls. 977 
g, Immunoblot analysis of N4BP1 in control and N4BP1 KO JNLGFP cells generated 978 
by the CRISPR/Cas9 system. β-Actin was used as loading control. 979 




h-i, N4BP1 KO JNLGFP cells were inducibly reconstituted with WT or R509A N4BP1 980 
by the Tet-on system via Dox treatment, followed by stimulation with PMA (10 ng/ml) 981 
for 24 hours. Cell lysates and culture supernatants were collected and immunoblot 982 
analysis was performed to determine the expression of N4BP1, Gag and β-Actin 983 
proteins (h). The ratio of p24 expression in the culture supernatants between Dox (-) 984 
controls and Dox (+) WT or R509A N4BP1 expressing cells examined in (h) is shown 985 
in (i) (n = 3). Individual points and means ± s.d. are shown.  986 
P values were calculated using unpaired two-tailed Student’s t-test. *P < 0.05, **P < 987 
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Supplementary Figure 1. N4BP1 inhibits various clones of HIV-1, HIV-2 and SIVcpzPtt.
HEK293T cells were transfected with proviral clones expressing NL4-3, AD17 (TF), CH058
(TF), CH200v2 (TF), CH058 (6-mo), CH077 (6-mo), CH042 (CC), CH534 (CC), CH440 (CC),
GH123 (HIV-2) or MB897 (SIVcpzPtt) (250 ng each), together with the N4BP1 expression
plasmid (250 ng). Forty eight hours post-transfection, a TZM-bl reporter assay was performed
to measure the production of infectious virus in the cell culture supernatants. Infectious virus
yields normalized to the empty vector control are shown as mean values ± s.d. of biological

































































Primary human CD4+ T cells
b
Supplementary Figure 2. N4BP1 expression is induced by various IFN-a subtypes
in human primary CD4+ T cells.
(a) Immunoblot analysis for the expression of N4BP1 in human primary CD4+ T cells
stimulated with indicated IFN-a subtypes (50 ng/ml each) or IL-27 (5 ng/ml) for 3 days. b-
Actin was used as loading controls. Data are representative of three independent
experiments.
(b) N4BP1 expression levels were determined by immunoblotting as shown in (a) and
normalized to b-actin levels. The unstimulated sample was set to 100%. Data shown are
mean values ± s.d. of immunoblot data derived from 3 individual donors. P values were































































































































































Supplementary Figure 3. N4BP1 deficiency in Jurkat cells does not affect growth, cell
death or global protein synthesis
(a) N4BP1 KO Jurkat cells (clones 1 and 2) and control (Cont) cells were cultivated for 2 and
4 days and changes in cell numbers are shown. Data are shown as mean± s.d. of biological
replicates (n = 3).
(b) Cells in a were analyzed by Flow cytometry (FACSVerse; BD) after propidium iodide
staining. Individual points and means± s.d. are shown (n = 3).
(c) Control and N4BP1 KO Jurkat cells were cultured for 1 day. As negative control, some
control cells were treated with a protein synthesis inhibitor, Cycloheximide (Cayman
Chemical) for 30 min. Then the cells were harvested, and translating polypeptides were
labeled with O-Propargyl-Puromycin (OPP) for 30 min at 37 °C followed by staining with 5
FAM Azide using the Protein Synthesis Assay kit (Cayman Chemical). The cells were
analyzed by Flow cytometry (FACSVerse; BD). Representative histograms for the levels of
translating polypeptides (FAM) are shown (Left panel). Mean Fluorescence Intensities from
the experiments were shown in the right panel. n = 3 biologically independent samples.















































































































































































































































































Supplementary Figure 4. N4BP1 deficiency does not affect the expression of a set of
house keeping genes, genes involved in cell cycling, apoptosis, IFN responses, IL17A
and IL22 in N4BP1 KO Jurkat cells.
(a) Total RNA was prepared from control and N4BP1 KO Jurkat cells cultured for 1 day, and
expression levels of the indicated genes including house-keeping genes (GAPDH, ACTB or
HPRT), the anti-apoptotic gene BCL2, cell cycle-related genes (MYC, CDK9, CCNT1, CDK2
and BRD4), IFNB and inflammatory and anti-inflammatory genes (NFKBIA, IL17A and IL22)
were determined by RT-qPCR. ​Individual points and means ± s.d. are shown. Data are from
n = 3 biologically independent samples.
(b) Cell lysates were prepared from control and N4BP1 KO Jurkat cells cultured for 1 day,
and the expression of N4BP1, GAPDH, Tubulin-a and IkBa proteins was determined by










































































































































































































































































































































































































































































Supplementary Figure 5. N4BP1 restricts HIV-1 in Jurkat cells.
(a) N4BP1 expression levels were determined by RT-qPCR in Jurkat cells transfected with
N4BP1 specific siRNA for 72 hours. n = 3 biological replicates. Individual points and means
± s.d. are shown.
(b and c) siRNA-treated Jurkat cells were infected with HIV-1 NL4-3. Seventy two hours post-
infection, IFNB and viral mRNA expression levels in the cell lysates (b) and the culture
supernatants (c) were determined by qPCR. n = 3 biological replicates. Individual points and
means± s.d. are shown.
(d) Immunoblot analysis for Flag-tagged N4BP1, endogenous N4BP1 and b-Actin in cell
lysates from Jurkat cells stably expressing N4BP1.
(e) Expression levels of tat/rev, vif or gag RNA were measured by qPCR in Jurkat cells stably
expressing N4BP1 or the respective parental cell line following infection with HIV-1 for the
indicated periods. ​Data are shown as mean values± s.d. of technical replicates (n = 3).
(f) N4BP1-stably expressing Jurkat cells and control cells were infected with VSV-G-
pseudotyped HIV-1 NL4-3 Δenv. Forty eight hours post infection, culture supernatants (Sup)
and cell lysates were collected and analyzed by immunoblotting for the expression of Gag
p24 in the culture supernatants (Sup), and N4BP1 and b-Actin in cell lysates.
P values were calculated using unpaired two-tailed Student’s t-test. *P < 0.05; **P < 0.01;

































































Supplementary Figure 6. N4BP1 does not suppress influenza virus.
(a) HEK293T cells stably expressing N4BP1 or control cells were infected with Influenza A
virus (PR8 strain) for 24 hours before the expression level of viral mRNA for segment 4 (HA)
was measured by qPCR. N.D., Not detected. n = 3 biological replicates. Individual points and
means± s.d. are shown.
(b) HEK293T cells stably expressing N4BP1 or control cells were infected with Influenza A
virus (WSN strain) at an MOI of 1 X 10-3, and the culture media were harvested 24 hours
postinfection. The virus titers were determined by using plaque assays on MDCK cells.
















Supplementary Figure 7. N4BP1 inhibits HIV-1 at the post-transcriptional level.
(a) LTR promotor activity was determined in TZM-bl cells cotransfected with N4BP1 and
HIV-1 NL4-3 Denv expressing plasmids. n = 3 biological replicates. Individual points and
means± s.d. are shown.
(b) Schematic representation of plasmids used in (c). The pEGFPC1 plasmid (Clontech)
expresses EGPF protein under the control of CMV promoter. pCMV259 expresses HIV-1
NL4-3 under the CMV promoter instead of LTR (pNL4-3).
(c) HEK293T cells were transfected with pEGFP-C1 or pCMV259 together with or without
Flag-N4BP1 plasmids. Expression of Gag p24 in the culture supernatants (Sup) as well as
the expression of Flag-N4BP1, GFP, Gag and b-Actin in the cell lysates were determined
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Supplementary Figure 8. N4BP1 inhibits HIV-1 at the late stage depending on its
RNase activity.
(a) Purified N4BP1 was subjected to the in vitro cleavage assay using [32P]-labeled RNA
derived from a part of the pBluescript vector.
(b) Multiple sequence alignment of the N4BP1 and Regnase-1 RNase domains. Arrows
indicate conserved Asp residues in the catalytic domain.
(c) N4BP1 knockdown Jurkat cells exposed to HIV-1 NL4-3 (MOI; 0.1) or heat-inactivated
HIV-1 NL4-3 at 37°C for 2 hours. Total DNA was isolated 12 hours after treatment, and
amounts of early RT (R/U5) and late RT (U5/gag) products and integrated provirus were
quantified by qPCR in. n = 3 biological replicates. Individual points and means ± s.d. are
shown.
(d) HEK293T cells were cotransfected with pNL4-3 and vectors expressing N4BP1 or N4BP1
D623N. Shown are the immunoblots for the expression of Vif, Vpu, Nef and Vpr in cell lysates
prepared 48 hours after transfection.
(e and f) HEK293T cells were transfected with WT or D623N N4BP1 plasmids and cells were
counted (e) or analyzed by flow cytometry after propidium iodide staining (f) 48 h later. Data
are mean ± s.d. of biological replicates. Data are representative three (c and d) and two (a)
independent experiments.
Supplementary Figure 9. N4BP1 is not antagonized by accessory proteins of HIV-1
NL4-3.
HEK293T cells were transfected with an expression plasmid for N4BP1, Tetherin or empty
vector together with NL4-3 wild type or NL4-3 Δ4. The latter does not express any of the
accessory proteins encoded by HIV-1 (i.e. Vpu, Vif, Vpr and Nef). Infectious virus production
was measured by TZM-bl assay 48 hours after transfection = 3 biological replicates.
Individual points and means ± s.d. are shown. P values were calculated using unpaired two-
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Supplementary Figure 10. N4BP1 is degraded by MALT1 and contribution of other
MALT1 substrates in the inhibition of HIV-1.
(a) Expression levels of N4BP1 mRNA were determined by RT-qPCR in Jurkat cells
stimulated with PMA (50 ng/ml) plus ionomycin (1 mM) for the indicated periods of time. Data
are shown as mean± s.d. of biological replicates (n = 3).
(b) N4BP1 expression levels were determined by immunoblotting in cell lysates from Jurkat
cells stimulated with PMA plus ionomycin for 1 hour with or without the indicated
concentrations of proteasome inhibitor MG132. b-Actin was used as loading controls. Data
are representative of three independent experiments.
(c) Immunoblot analysis of N4BP1 in cell lysates from Jurkat cells stimulated with PMA (50
ng/ml), ionomycin (1 mM) or PMA plus ionomycin for 1 hour. b-Actin was used as loading
controls. Data are representative of three independent experiments.
(d) HEK293T cells were co-transfected with pNL4-3 and the indicated expression plasmids
encoding Regnase-1, Rouqin-1 and Roquin-2. Forty eight hours post-transfection, a TZM-bl
reporter assay was performed to measure the production of infectious virus in the cell culture
supernatants. Infectious virus yields normalized to the empty vector control are shown as
mean values ± s.d. derived from of biological replicates (n = 3). P values were calculated
using unpaired two-tailed Student’s t-test. ***P < 0.005.









Supplementary Figure 11. MALT1 contributes to viral reactivation in latently infected 
cells.
(a, b and c) Immunoblot analysis of N4BP1 in cell lysates from J-Lat10.6 (a), JNLGFP (b) or
J-Lat5A8 (c) cells stimulated with PMA (50 ng/ml) for the indicated periods of time. b-Actin
was used as loading controls. Data are representative of three independent experiments.
(d) Immunoblot analysis of N4BP1 and MALT1 in cell lysates from MALT1-deficient or control
J-Lat5A8 cells stimulated with PMA (50 ng/ml) for 24 hours. b-Actin was used as loading
controls. Data are representative of three independent experiments.
(e) Expression of tat/rev and gag mRNAs was quantified by qPCR in MALT1-deficient or
control J-Lat5A8 cells stimulated with PMA (50 ng/ml) for the indicated periods. Data are
shown as mean ± s.d. of biological replicates (n = 3). P values were calculated using
unpaired two-tailed Student’s t-test. **P < 0.01; ***P < 0.005.

























































Supplementary Figure 12. Schematic model of the function of N4BP1 in inhibiting HIV-























Resting CD4+ T cells
(HIV-1 latency)
Supplementary Table 1. Genes used for the screening of proteins harboring RNA binding 
domains and inhibiting HIV-1 infection.  
 




No Gene Name 
Accession 
Number 
1 GPATCH4 BC056904  32 ZC3H7A BC027330 
2 GPATCH2 BC042193  33 IREBP1 BC018103 
3 GPATCH2 BC063474  34 ZCCHC17 BC050609 
4 FTSJD2 BC031890  35 ZC3H8 BC032001 
5 PINX1 BC015479  36 HNRNPC BC103758 
6 KIAA0391 BC032221  37 CPSF4 BC050738 
7 RBM5 BC046643  38 CPSF4L BC004603 
8 ZCCHC4 BC016914  39 Zc3h15 BC031845 
9 NKRF BC047878  40 Zc3h14 BC024824 
10 GPATCH8 BC019948  41 Zc3h11a BC005786 
11 GPATCH4 BC056904  42 ZFP36L1 BC018340 
12 GPATCH3 BC096468  43 TIAL1 BC010496 
13 SRRD BC017682  44 Zc3h18 BC030495 
14 RBM10 BC004674  45 HNRNPD BC011172 
15 RBM6 BC026129  46 Zcchc6 BC023880 
16 ARFRP1 BC010713  47 Zc3h6 BC043311 
17 ARFPR1 BC021513  48 HNRNPK BC006694 
18 ZCCHC9 BC032736  49 N4BP1 BC004022 
19 PNPT1 BC027228  50 PCBP3 BC042440 
20 QKI BC019917  51 PCBP4 BC010694 
21 ANKHD1 BC040231  52 KHDRBS1 BC002051 
22 FXR1 BC019139  53 RNF141 BC018104 
23 TARDBP BC071657  54 RNF11 BC020964 
24 YTHDC1 BC053863  55 RNF32 BC015416 
25 YTHDC1 BC041119  56 PCBP2 BC107688 
26 RIG-I BC015946  57 RNF7 BC008627 
27 FUBP1 BC014763  58 RNF138 BC018107 
28 ZCCHC7 BC036940  59 RNF6 BC034688 
29 ZCCHC11 BC048301  60 IGF2BP3 BC065269 
30 ZCCHC18 BC017627,  61 RNF213 BC032220 





Supplementary Table 2. RT-qPCR Primer Sets 
Accession No Gene Forward Reverse 
AF324493.2 Tat/Rev 5′-ATGGCAGGAAGAAGCGGAG-3′ 5′-ATTCCTTCGGGCCTGTCG-3′ 
AF324493.2 Gag2 5′-GTGTGGAAAATCTCTAGCAGTGG-3′ 5′-CGCTCTCGCACCCATCTC-3′ 
AF324493.2 Gag3 5′-GTGTGGAAAATCTCTAGCAGTGG -3′ 5′-CGCTCTCGCACCCATCTC -3′ 
AF324493.2 Vif 5′-GGCGACTGGGACAGC -3′ 5′-CACACAATCATCACCTGCC -3′ 
NM_153029.4 N4BP1 5′- CCCGATGATCCTCTGGGAAG -3′ 5′- TTTGGCAGGGCACTGAGTAG -3′ 
NM_004335.4 Tetherin 5′- GTGTCGCAATGTCACCCATC -3′ 5′- GGGAAGCCATTAGGGCCATC -3′ 
NM_002176.4 IFN- 5′- TTGTTGAGAACCTCCTGGCT -3′ 5′- TGACTATGGTCCAGGCACAG -3′ 
X03205.1 18S 5′- CGGACAGGATTGACAGATTG -3′ 5′- CAAATCGCTCCACCAAGTAA -3′ 





5′- GGCCCAACCACAACACAACC -3 5′- AGCCCTCCTTCTCCGTCAGC -3 
AF324493.2 HIV-1 Total 5′- CCTCAGATGCTGCATATAAG -3 5′- CAGGCTCAGATCTGGTCTAA -3 
NC_001501 MLV gag 5′- GTCTGAGAATATGGGCCAGA -3 5′- CTTGATCTTAACCTGGGTGA-3 
X52154.1 SIVcpzPtt 5′- ACATCTAGTATGGGCCGGAA -3 5′- TTCTGGAGAACCAATGTCTACC -3′ 









5′- CAGCATCGCCCCACTTGATTTTGG -3′ 
NM_001101.5 ACTB 5′- GCGAGAAGATGACCCAGATC -3′ 5′- CCAGTGGTACGGCCAGAGG -3′ 
NM_000194.3 HPRT1 5′- TATGGCGACCCGCAGCCCT -3′ 5′- CATCTCGAGCAAGACGTTCAG -3′ 
NM_000633.2 
NM_000657.2 
BCL2 5′- TCCCTCGCTGCACAAATACTC -3′ 5′- ACGACCCGATGGCCATAGA -3′ 
NM_001354870.1 
NM_002467.6 
cMYC 5′- GCGTCCTGGGAAGGGAGATCCGGAGC -3′ 
5′- TTGAGGGGCATCGTCGCGGGAGGC TG -
3′ 
NM_001261.3 CDK9 5′- ATGGCAAAGCAGTACGACTCG -3′ 5′- GCAAGGCTGTAATGGGGAAC -3′ 
NM_001240.4 CCNT1 5′- ACAACAAACGGTGGTATTTCACT -3′ 5′- CCTGCTGGCGATAAGAAAGTT -3′ 









BDR4 5′- ACCTCCAACCCTAACAAGCC -3′ 5′- TTTCCATAGTGTCTTGAGCACC -3′ 
NM_020529.2 NFKBIA 5′- GAGGAGTACGAGCAGATGGTC -3′ 5′- CAGGTTGTTCTGGAAGTTGAG -3′ 
NM_002190.3 IL17A 5′- CAACCGATCCACCTCACCTT -3′ 5′- GGCACTTTGCCTCCCAGAT -3′ 
NM_020525.5 IL22 5′- GCAGGCTTGACAAGTCCAACT -3′ 5′- GCCTCCTTAGCCAGCATGAA -3′ 
Supplementary Table 3. Sequence used for in vitro transcription and in vitro cleavage assay 










































































































































HIV-1 RNA probe 18s
HIV-1 NL4-3



















































































































































Anti-N4BP1 Anti-MALT1 Anti-β-Actin Anti-N4BP1 Anti-MALT1 Anti-β-Actin









































































































































































































Anti-β-Actin Anti-p24 Anti-N4BP1 Anti-p24Anti-GFP























































































































* Bcl-2 carry over
*
43
